Commentary to STAMPEDE, CHAARTED and LATITUDE studies from the urologist and clinical oncologist points of view Commentary
Article Sidebar
Published:
Sep 30, 2018
Keywords:
prostate cancer, hormonal therapy, docetaxel, abiraterone
Main Article Content
Abstract
Hormonal therapy that lowering serum testosterone levels is an essential treatment for patients with advanced prostate cancer. STAMPEDE, CHAARTED and LATITUDE studies showed that early addition of docetaxel or abiraterone for hormonal treatment significantly prolongs survival of the patients compared to those in whom the treatment was introduced at the time of progression of the neoplastic disease.
Article Details
How to Cite
Dobruch, J., & Drobniak , A. (2018). Commentary to STAMPEDE, CHAARTED and LATITUDE studies from the urologist and clinical oncologist points of view. Medycyna Faktow (J EBM), 11(3(40), 216-223. https://doi.org/10.24292/01.MF.0318.8
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Torre L.A., Bray F., Siegel R.L. et al.: Global cancer statistics 2012. C.A. Cancer J. Clin. 2015; 65: 87-108.
2. Paquette E.L., Sun L., Paquette L.R. et al.: Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002; 60: 756-759.
3. Weiner A.B., Matulewicz R.S., Eggener S.E., Schaeffer E.M.: Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016; 19: 395-397.
4. Kitagawa Y., Namiki M.: Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. Asian J. Androl. 2015; 17: 475-480.
5. Huggins C., Hodges C.V.: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-297.
6. Walsh P.C.: Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol. Clin. N. Am. 1975; 2: 125-140.
7. Denis L.: Prostate cancer. Primary hormonal treatment. Cancer 1993; 71: 1050-1058.
8. Hellerstedt B.A., Pienta K.J.: The current state of hormonal therapy for prostate cancer. C.A. Cancer J. Clin. 2002; 52: 154-179.
9. Petrylak D.P., Tangen C.M., Hussain M.H. et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 1513-1520.
10. Tannock I.F., de Wit R., Berry W.R. et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502-1512.
11. Sweeney C.J., Chen Y.H., Carducci M. et al.: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 2015; 373: 737-746.
12. James N.D., Sydes M.R., Clarke N.W. et al.: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163-1177.
13. Fizazi K., Tran N., Fein L. et al.: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 2017; 377: 352-360.
14. Gravis G., Boher J.M., Chen Y.H. et al.: Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur. Urol. 2018; 73(6): 847-855. DOI: 10.1016/j.eururo.2018.02.001.
15. Mottet N., De Santis M., Briers E. et al.: Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. Eur Urol. DOI: 10.1016/j.eururo.2017.09.029.
16. Sydes M.R., Spears M.R., Mason M.D. et al.: Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 2018; 29(5): 1235-1248. DOI: 10.1093/annonc/mdy072.
17. Østergren P.B., Kistorp C., Fode M. et al.: Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. J. Urol. 2017; 197: 1441-1447.
2. Paquette E.L., Sun L., Paquette L.R. et al.: Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002; 60: 756-759.
3. Weiner A.B., Matulewicz R.S., Eggener S.E., Schaeffer E.M.: Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016; 19: 395-397.
4. Kitagawa Y., Namiki M.: Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. Asian J. Androl. 2015; 17: 475-480.
5. Huggins C., Hodges C.V.: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-297.
6. Walsh P.C.: Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol. Clin. N. Am. 1975; 2: 125-140.
7. Denis L.: Prostate cancer. Primary hormonal treatment. Cancer 1993; 71: 1050-1058.
8. Hellerstedt B.A., Pienta K.J.: The current state of hormonal therapy for prostate cancer. C.A. Cancer J. Clin. 2002; 52: 154-179.
9. Petrylak D.P., Tangen C.M., Hussain M.H. et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 1513-1520.
10. Tannock I.F., de Wit R., Berry W.R. et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502-1512.
11. Sweeney C.J., Chen Y.H., Carducci M. et al.: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 2015; 373: 737-746.
12. James N.D., Sydes M.R., Clarke N.W. et al.: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163-1177.
13. Fizazi K., Tran N., Fein L. et al.: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 2017; 377: 352-360.
14. Gravis G., Boher J.M., Chen Y.H. et al.: Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur. Urol. 2018; 73(6): 847-855. DOI: 10.1016/j.eururo.2018.02.001.
15. Mottet N., De Santis M., Briers E. et al.: Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. Eur Urol. DOI: 10.1016/j.eururo.2017.09.029.
16. Sydes M.R., Spears M.R., Mason M.D. et al.: Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 2018; 29(5): 1235-1248. DOI: 10.1093/annonc/mdy072.
17. Østergren P.B., Kistorp C., Fode M. et al.: Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. J. Urol. 2017; 197: 1441-1447.